Department: DRUG CHALLENGE
Can you identify inhalation products and nasal sprays available for treating pulmonary conditions such as chronic obstructive pulmonary disease (COPD), asthma, and allergic rhinitis? Match the medications in Section I with the description in Section II.
_____ 1. Arcapta (Novartis)
_____ 2. Daliresp (Forest Pharmaceuticals)
_____ 3. Qnasl (Teva Pharmaceutical)
_____ 4. Arnuity Ellipta (GlaxoSmithKline)
a. beclomethasone dipropionate nasal aerosol. This once-daily nasally inhaled corticosteroid is indicated for relief of seasonal and perennial allergic rhinitis symptoms in patients age 4 and older. Avoid use in patients with recent nasal ulcers, nasal surgery, or nasal trauma.
b. roflumilast. A once-daily oral tablet, this selective phosphodiesterase 4 inhibitor is indicated to reduce the risk of exacerbations in patients with severe COPD. It's not a bronchodilator and isn't indicated for the relief of acute bronchospasm.
c. fluticasone furoate inhalation powder. Inhaled once a day, this new corticosteroid is indicated for maintenance treatment of asthma in patients age 12 or older. Teach patients to rinse their mouth with water and spit out the water after inhalation to reduce the risk of oral thrush.
d. indacaterol maleate inhalation powder. A once-daily long-acting beta2 receptor agonist, this drug is indicated as maintenance therapy for COPD. The patient uses the provided inhalation device to puncture a capsule containing the drug and inhale its dry powder contents.
Resources available on request.
ANSWERS: 1d, 2b, 3a, 4c